Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD
AMP-AD 中疾病亚分类和目标优先级的代谢组学特征
基本信息
- 批准号:10084547
- 负责人:
- 金额:$ 12.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-13 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAminesAnimalsAtlasesBile AcidsBindingBiochemicalBiochemical PathwayBiological MarkersBiological ModelsBlood specimenBrainBrain DiseasesBrain imagingBranched-Chain Amino AcidsCardiovascular DiseasesChemicalsCholesterolClassificationClinicalClinical TrialsCognitionCognitiveCommunitiesDataDatabasesDevelopmentDiabetes MellitusDiseaseDrug TargetingDrug usageEarly InterventionEnzymesFailureFluorouracilFramingham Heart StudyFunctional disorderGene ExpressionGeneticGenetic VariationGenomeGenotypeGlucoseGlutamatesGoalsHeterogeneityHumanImpaired cognitionKnowledgeLeadLecithinLife StyleLinkMalignant NeoplasmsMeasuresMedicalMetabolicMetabolic PathwayMetabolismMolecularMonitorNetwork-basedNeurotransmittersPathogenesisPathway interactionsPatientsPeripheralPharmaceutical PreparationsPhasePreventionProxyResearchRiskRisk FactorsRoleSamplingSignal TransductionSignaling MoleculeSphingomyelinsStratificationStructureSymptomsTimeTranslationsTryptophanTyrosineVertebral columnWorkbiomarker developmentbrain healthclinical phenotypeclinical subtypescohortcytotoxicdisease phenotypedisorder subtypedrug developmentdrug discoverygut microbiomeinsightmetabolic phenotypemetabolomicsnetwork modelsneuroimagingnew therapeutic targetnovel therapeuticsprecision medicineprotein expressionresearch clinical testingsextooltreatment response
项目摘要
Abstract/Scope of Work
Failures of Alzheimer disease (AD) clinical trials calls for a research paradigm shift. AMP-AD has
the central goal of shortening the time between the discovery of potential drug targets and
development of new drugs for AD. Large data generated by the six participating consortia has
identified over 20 potential targets for novel drug discovery. The next challenge is to provide
deeper molecular understanding of common pathways implicated and the key enzymes,
transporters and signaling molecules that are most amenable for drug discovery and for lead
identification.
The AD Metabolomics Consortium (ADMC), as part of AMP-AD and M2OVE-AD, began to
address these and other challenges by building a comprehensive metabolomics database and an
Atlas for AD. Metabolomic signatures serve as a readout capturing net influences of (epi)genetic
variation, protein expression, gut microbiome and environmental and lifestyle differences.
Metabolic signatures can inform about disease mechanisms, progression, heterogeneity and
treatment response. Basic biochemical knowledge has impacted the medical field and provided
basic tools for monitoring disease such as measures of glucose and cholesterol in diabetes and
cardiovascular diseases and resulted in development of key drugs targeting these disorders.
Defining metabolic trajectories of those at risk for and with AD can similarly enable drug discovery.
In AMP-AD Phase I, the ADMC profiled 1,600 baseline samples from the AD Neuroimaging
Initiative (ADNI) using 8 metabolomics platforms measuring over 800 metabolites. We identified
metabolic signatures for AD that correlate with markers of AD pathophysiology including
cognition, as well as gut-derived metabolites involved in cholesterol clearance related to brain
imaging changes and cognitive decline. As a first step towards patient sub-stratification, we
investigated sex- and APOE-specific metabolic signatures. Within an atlas being developed, we
connect AD metabolomic signatures with the genome. Utilizing these metabolic signatures we
annotated AMP-AD targets with implicated metabolic pathways, illustrating the power of
metabolism to inform drug development.
For Phase II of AMP-AD, we propose to more thoroughly address challenges in order to
accelerate AMPAD progress toward novel drug discovery. We will connect central and peripheral
metabolic changes addressing contributions of peripheral metabolism to brain health and disease,
enable AMPAD partners with biochemical readouts that connect their findings to known
biochemical pathways that can be targeted for drug discovery; define early changes that can
provide insights about causative mechanisms and early interventions; use metabotypes and
genotypes to identify clinical subtypes to support a precision medicine approach to AD; and
identify lead compounds with the possibility to repurpose existing drugs for AD.
摘要/工作范围
阿尔茨海默氏病(AD)临床试验的失败要求进行研究范式转变。 Amp-ad有
缩短发现潜在药物靶标之间时间的核心目标和
开发AD的新药。六个参与财团生成的大数据
确定了20多个新型药物发现的潜在靶标。下一个挑战是提供
对所涉及的公共途径和关键酶的更深入的分子理解,
最适合药物发现和铅的转运蛋白和信号分子
鉴别。
作为AMP-AD和M2OVE-AD的一部分,广告代谢组学联盟(ADMC)开始
通过构建全面的代谢组学数据库来应对这些挑战和其他挑战
Atlas for Ad。代谢组签名是捕获(EPI)遗传的净影响的读数
变异,蛋白质表达,肠道微生物组以及环境和生活方式差异。
代谢特征可以告知疾病机制,进展,异质性和
治疗反应。基本的生化知识影响了医学领域并提供了
监测疾病的基本工具,例如糖尿病中的葡萄糖和胆固醇的措施
心血管疾病,导致针对这些疾病的关键药物的发展。
定义有风险和AD风险的人的代谢轨迹可以类似地发现药物。
在AMP-AD阶段,ADMC介绍了来自AD神经影像学的1,600个基线样品
倡议(ADNI),使用8个代谢组学平台,测量超过800个代谢产物。我们确定了
与AD病理生理标记相关的AD代谢特征
认知以及与大脑有关的胆固醇清除率涉及的肠道衍生代谢产物
成像变化和认知能力下降。作为迈向患者子分层的第一步,我们
研究了性别和特异性的代谢特征。在开发的地图集中,我们
将AD代谢组信号与基因组联系起来。利用这些代谢特征我们
带有牵涉代谢途径的注释的AMP-AD目标,说明了
代谢为药物开发提供信息。
对于AMP-AD的第二阶段,我们建议更彻底地应对挑战
加速AMPAD朝着新的药物发现前进。我们将连接中央和周边
代谢变化解决周围代谢对大脑健康和疾病的贡献,
启用AMPAD合作伙伴与生化读数,将其发现与已知的发现联系起来
可以针对药物发现的生化途径;定义可以的早期变化
提供有关因果机制和早期干预措施的见解;使用代谢型和
鉴定临床亚型以支持Precision Medicine AD方法的基因型;和
识别铅化合物,有可能重新利用现有药物进行AD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rima F Kaddurah-Daouk其他文献
Rima F Kaddurah-Daouk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rima F Kaddurah-Daouk', 18)}}的其他基金
Project 3 - Mechanistic studies on role of gut microbiome in models for Alzheimer's disease
项目 3 - 肠道微生物组在阿尔茨海默病模型中作用的机制研究
- 批准号:
9795005 - 财政年份:2019
- 资助金额:
$ 12.5万 - 项目类别:
Project 3 - Mechanistic studies on role of gut microbiome in models for Alzheimer's disease
项目 3 - 肠道微生物组在阿尔茨海默病模型中作用的机制研究
- 批准号:
10017880 - 财政年份:2019
- 资助金额:
$ 12.5万 - 项目类别:
Project 2 - Influence of controlled diets on gut microbiome, metabolome and cognitive function
项目 2 - 控制饮食对肠道微生物组、代谢组和认知功能的影响
- 批准号:
9795004 - 财政年份:2019
- 资助金额:
$ 12.5万 - 项目类别:
Project 2 - Influence of controlled diets on gut microbiome, metabolome and cognitive function
项目 2 - 控制饮食对肠道微生物组、代谢组和认知功能的影响
- 批准号:
10017878 - 财政年份:2019
- 资助金额:
$ 12.5万 - 项目类别:
Project 1 - Changes in Gut Microbiome and related Metabolome Across Trajectory of Alzheimer's Disease
项目 1 - 阿尔茨海默氏病轨迹中肠道微生物组和相关代谢组的变化
- 批准号:
10017875 - 财政年份:2019
- 资助金额:
$ 12.5万 - 项目类别:
相似海外基金
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 12.5万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 12.5万 - 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
- 批准号:
10462257 - 财政年份:2023
- 资助金额:
$ 12.5万 - 项目类别: